BioRestorative Q1 FY26 net loss narrows to $2.15 million; revenue falls 7.32% to $23,170

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.

BRTX

0.00
  • BioRestorative Therapies posted a net loss of USD 2.15 million for the quarter ended March 31, 2026, narrowing from a year-earlier net loss of USD 5.34 million.
  • Revenue slipped 7.32% to USD 23,170, reflecting USD 11,870 of product revenue and USD 11,300 of royalty revenue; royalty revenue fell 54.8% on fewer disc procedures performed by its sublicensee.
  • Operating loss narrowed to USD 3.39 million as total operating expenses fell to USD 3.4 million, led by research and development expense of USD 1.93 million.
  • Cash and cash equivalents rose to USD 3.11 million at March 31, 2026 from USD 1.51 million at Dec. 31, 2025, while working capital swung to USD 2.19 million from a USD 586,029 deficiency.
  • Management flagged substantial doubt about its ability to continue as a going concern, citing insufficient cash for at least 12 months after issuance of the financial statements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023126), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.